These reactions occur as a result of the subcutaneous administration of the medication, which involves injecting the solution into the fatty tissue beneath the skintypically in the abdomen, thigh, or upper arm
Invitrogen), HEPES (10 mmol/L
- [SURMOUNT-1: Tirzepatide for Treatment of Obesity]( *New England Journal of Medicine*, 2022
Nat Rev Endocrinol 8:728742 Gough SC, Bode B, Woo V et al (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
TB-500 reduces glial scarring, promotes repair cell migration, and supports angiogenesis through complementary mechanisms